Beroctocog alfa
- Generic Name
- Beroctocog alfa
- Brand Names
- Alphanate
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9001-27-8
- Unique Ingredient Identifier
- 17RNR4H479
- Indication
Beroctocog alfa is indicated for the prevention and control of bleeding in patients with hemophilia A or acquired Factor VIII (FVIII) deficiency. It is also indicated for surgical/invasive procedures in adult and pediatric patients with von Willebrand Disease in who desmopression is either ineffective or contraindicated. It is not indicated for patients with severe (i.e. type 3) von Willebrand Disease whom are undergoing major surgery.
- Associated Conditions
- Bleeding
- Associated Therapies
- Perioperative management therapy
US FDA approves Pfizer's drug for rare bleeding disorder
Pfizer's Hympavzi, a once-a-week injection, received FDA approval for treating haemophilia A or B in patients aged 12 and older. The drug aims to reduce treatment burden and showed a 92% reduction in bleeding episodes in a late-stage study. Hympavzi is Pfizer's second haemophilia treatment approved this year, with potential sales of $300 million by 2030.
USFDA approves Pfizer's marstacimab-hncq for treatment of hemophilia A or B
FDA approves Pfizer's HYMPAVZI, the first anti-TFPI for hemophilia A or B, administered via a pre-filled auto-injector pen, offering a once-weekly subcutaneous treatment option.
Treatment options for hemophilia A
Hemophilia A, caused by F8 gene mutation, leads to factor VIII deficiency, impairing blood clotting. Treatment includes factor VIII replacement, immunotherapies, and gene therapy, aiming to manage bleeding and prevent inhibitor development.
U.S. FDA Approves Pfizer's HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults ...
FDA approves HYMPAVZI™ for routine prophylaxis in hemophilia A or B without inhibitors, offering a once-weekly subcutaneous treatment with a manageable safety profile and minimal preparation.
U.S. FDA Approves Pfizer's HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults
U.S. FDA approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for hemophilia A or B without inhibitors, based on Phase 3 study results showing substantial bleed reduction. HYMPAVZI is the first once-weekly subcutaneous prophylactic treatment for hemophilia B and the first to use a pre-filled pen or syringe for hemophilia A or B.
FDA Approves Marstacimab-hncq (Hympavzi) for Hemophilia A or B Without Inhibitors
The FDA approved Pfizer’s marstacimab-hncq (Hympavzi) for hemophilia A/B without inhibitors, reducing annualized bleeding rates by 35% and 92% compared to routine prophylaxis and on-demand treatment. The drug, administered via a pre-filled auto-injector pen, marks a significant advancement in hemophilia treatment.
FDA Approves Hympavzi (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
FDA approves Hympavzi (marstacimab-hncq) for hemophilia A or B without inhibitors, offering a once-weekly subcutaneous treatment option.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath